- Trials with a EudraCT protocol (28)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
28 result(s) found for: Antithrombin III.
Displaying page 1 of 2.
EudraCT Number: 2021-004307-40 | Sponsor Protocol Number: ATN-106 | Start Date*: 2022-01-31 | |||||||||||
Sponsor Name:Octapharma AG | |||||||||||||
Full Title: A multicentre, prospective, open-label, uncontrolled Phase 3 study to assess the efficacy, safety and pharmacokinetics of Atenativ in patients with congenital antithrombin deficiency undergoing sur... | |||||||||||||
Medical condition: Congenital antithrombin deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004534-23 | Sponsor Protocol Number: GATRA2016 | Start Date*: 2017-04-11 | |||||||||||||||||||||
Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO | |||||||||||||||||||||||
Full Title: Pilot study of Antithrombin supplementation during Extracorporeal Membrane Oxigenation | |||||||||||||||||||||||
Medical condition: Adult patients requiring veno-venous Extracorporeal circulation (ECMO) as a support for respiratory failure | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001659-42 | Sponsor Protocol Number: ANTITROMBINA | Start Date*: 2020-04-18 | ||||||||||||||||
Sponsor Name:Fundación para la Investigación Biomédica de Córdoba | ||||||||||||||||||
Full Title: Pilot study of antithrombin as prophylaxis of acute respiratory distress syndrome in patients with COVID-19 | ||||||||||||||||||
Medical condition: Confirmed SARS-CoV-2 respiratory infection with poor prognostic factors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003728-39 | Sponsor Protocol Number: Euro SPK 003 | Start Date*: 2010-12-07 |
Sponsor Name:Centre Hospitalier Universitaire de Liège | ||
Full Title: A EUROPEAN MULTICENTER OPEN-LABEL RANDOMIZED TRIAL TO EVALUATE THE REDUCTION OF ISCHEMIA / REPERFUSION INJURY AFTER DE NOVO SIMULTANEOUS PANCREAS/KIDNEY TRANSPLANTATION IN TYPE 1-DIABETIC PATIENTS ... | ||
Medical condition: End-stage, C-peptide-negative, type 1-diabetic patients undergoing a first combined pancreas/kidney transplantation from a cadaver donor only will be enrolled in the study | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-020377-16 | Sponsor Protocol Number: ATIII | Start Date*: 2009-11-20 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE | |||||||||||||
Full Title: EFFECTS OF THE ADMINISTRATION OF ANTITHROMBIN ON THE EMOCOAGULATIVE STATE AND ON THE INFLAMMATORY RESPONSE IN PATIENT WITH LOW PLASMATIC LEVELS OF ANTITHROMBIN AFTER CARDIAC INTERVENTIONS | |||||||||||||
Medical condition: Patients candidates for cardiac surgery intervention in extracorporeal circulation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-007313-68 | Sponsor Protocol Number: IG0801 | Start Date*: 2009-01-07 | |||||||||||
Sponsor Name:GRIFOLS ITALIA | |||||||||||||
Full Title: A Prospective Randomized Pilot study to evaluate the effect of preoperative antithrombin supplementation on postoperative levels of antithrombin in patients undergoing cardiac surgery with cardiopu... | |||||||||||||
Medical condition: Subjects undergoing elective cardiac surgery with Cardio Pulmonar Bypass (CPB) having baseline levels of ATIII activity equal to or higher than 60% and below 100% under all circumstances. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000099-12 | Sponsor Protocol Number: APHP180617 | Start Date*: 2021-10-12 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS | |||||||||||||
Full Title: Dose-adjustment of enoxaparin by a bayesian pharmacological approach in pediatric renal transplant recipients | |||||||||||||
Medical condition: Allograft vascular thrombosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001642-26 | Sponsor Protocol Number: LRD.2016.STREAM2 | Start Date*: 2017-10-02 | |||||||||||
Sponsor Name:Leuven Research & Development (LRD) at University of Leuven, Belgium | |||||||||||||
Full Title: STREAM-2 (STrategic Reperfusion in elderly patients Early After Myocardial Infarction) | |||||||||||||
Medical condition: ST-elevation myocardial infarction within 3 hours of onset of symptoms | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002328-34 | Sponsor Protocol Number: KB056 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:KEDRION S.P.A | |||||||||||||
Full Title: Efficacy and safety evaluation of Kedrion Fibrin Sealant as an adjuvant for the control of hemostasis in pediatric patients undergoing abdominal or orthopedic surgery. Multicenter, randomized, cont... | |||||||||||||
Medical condition: Paediatric patients undergoing abdominal or orthopedic surgery | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003359-12 | Sponsor Protocol Number: CCH2012-02 | Start Date*: 2015-02-18 | |||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||
Full Title: The effect of a high and low protamine-to-heparin dosing on perioperative hemostasis: a randomized clinical trial. | |||||||||||||
Medical condition: Patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001219-44 | Sponsor Protocol Number: 1123.28 | Start Date*: 2008-01-30 | |||||||||||
Sponsor Name:Boehringer Ingelheim France | |||||||||||||
Full Title: STREAM - STrategic Reperfusion Early After Myocardial Infarction Comparison of the efficacy and safety of a strategy of pre-hospital fibrinolytic treatment with tenecteplase and additional antipla... | |||||||||||||
Medical condition: ST-elevation myocardial infaction within 3 hours of onset of symptoms | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) AT (Completed) GB (Completed) IT (Completed) ES (Completed) BE (Completed) DE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002873-35 | Sponsor Protocol Number: LEO 90010-I21 | Start Date*: 2007-04-24 | ||||||||||||||||
Sponsor Name:LEO Pharmaceutical Products Ltd A/S (LEO Pharma A/S) | ||||||||||||||||||
Full Title: Exploratory efficacy and safety, pharmacokinetics and dose-finding study of ATryn® (antithrombin alfa) in patients with disseminated intravascular coagulation associated with severe sepsis | ||||||||||||||||||
Medical condition: Disseminated intravascular coagulation associated with severe sepsis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) FR (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) ES (Completed) DK (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-003866-96 | Sponsor Protocol Number: BEMI-2015 | Start Date*: 2016-04-29 | |||||||||||
Sponsor Name:ANGELA PUENTE | |||||||||||||
Full Title: Randomized controlled trial on the safety and efficacy of low molecular weight heparins in the prevention of thrombotic events in hospitalized cirrhotic patients | |||||||||||||
Medical condition: Prevention of thrombosis in cirrhotic patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005788-34 | Sponsor Protocol Number: NL79578.100.21 | Start Date*: 2022-03-31 |
Sponsor Name:St. Antonius Hospital | ||
Full Title: Platelet inhibition versus direct oral anticoagulation in patients undergoing percutaneous closure of patent foramen ovale or atrial septal defect | ||
Medical condition: Atrial septal defect or patent foramen ovale indicated for percutaneous closure with an occluder device. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2009-017095-24 | Sponsor Protocol Number: AOP13007 | Start Date*: 2010-02-17 | |||||||||||
Sponsor Name:AOP Orphan Pharmaceuticals AG | |||||||||||||
Full Title: A phase III, randomized, multicenter, subject- and sponsor-blinded, placebo controlled study to compare the efficacy and safety of “Anagrelide retard” versus placebo in “at risk” subjects with Esse... | |||||||||||||
Medical condition: male and female "at risk" subjects with Essential Thrombocythaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) SK (Completed) SI (Completed) LT (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020113-85 | Sponsor Protocol Number: CSLCT-BIO-l0-67 | Start Date*: 2011-09-20 | |||||||||||
Sponsor Name:CSL Behring GmbH | |||||||||||||
Full Title: A Multicentre, Interventional, Non-randomized, Open-label, Single-group Phase III Study to evaluate Plasma-Derived Antihaemophilic Factor/von Willebrand Factor Concentrate (Biostate®) for Immune To... | |||||||||||||
Medical condition: Male paediatric subjects with Haemophilia A who develped high titre antibodies to human coagulation Factor VIII | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Completed) AT (Completed) GR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001779-31 | Sponsor Protocol Number: FONDAPARINUX | Start Date*: 2008-05-09 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI | |||||||||||||
Full Title: Markers of hypercoagulability and risk of death and rehospitalization in heart failure patients: a pilot study on the effects of Fondaparinux | |||||||||||||
Medical condition: heart failure patients (III-IV NYHA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001239-30 | Sponsor Protocol Number: CIR976101 | Start Date*: 2012-05-22 | |||||||||||
Sponsor Name:Foundation for Liver Research | |||||||||||||
Full Title: THE EFFECTS OF RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 ON THE NUTRITIONAL STATUS IN PATIENTS WITH LIVER CIRRHOSIS: A PILOT-STUDY. | |||||||||||||
Medical condition: Liver cirrhosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000565-40 | Sponsor Protocol Number: GLM101-002 | Start Date*: 2022-11-04 | |||||||||||
Sponsor Name:Glycomine, Inc | |||||||||||||
Full Title: A Phase 2, Randomized, Open-Label, 12-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult Participa... | |||||||||||||
Medical condition: PMM2-CDG | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002211-10 | Sponsor Protocol Number: GRASPA-TNBC-2018-02 | Start Date*: 2019-03-20 | |||||||||||
Sponsor Name:ERYTECH Pharma | |||||||||||||
Full Title: A Randomized Phase 2/3 Study of Eryaspase in Combination with Gemcitabine and Carboplatin Chemotherapy versus Chemotherapy Alone for the Treatment of Patients with Metastatic or Locally Recurrent T... | |||||||||||||
Medical condition: Triple-Negative Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) BE (Completed) HU (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
